Amlostin 10 mg Tablets

Amlostin 10 mg Tablets:

Each tablet contains 10 mg of amlodipine (as amlodipine maleate).

For excipients, see Section 6.1

Tablet.

White round tablets with a break score on both sides.

Essential hypertension.

Chronic stable and vasospastic angina pectoris.

In adults

For treatment of both hypertension and angina pectoris the usual initial dose is 5 mg once daily. If the desired therapeutic effect cannot be achieved within 2-4 weeks, this dose may be increased to a maximum dose of 10 mg daily (as single dose) depending on the individual patient's response. Amlodipine may be used either as monotherapy or in combination with other antianginal drugs in patients with angina.

In children (less than 18 years of age)

Use of amlodipine in children is not recommended.

In the elderly

Normal dosage regimens are recommended in the elderly, but caution should be exercised when increasing the dosage (see section 5.2 “Pharmacokinetic properties”).

In patients with renal impairment

In these patients amlodipine can be used in the normal dosage (see section 5.2 “Pharmacokinetic properties”). Amlodipine is not dialysable.

In patients with hepatic impairment

A dosage regimen for patients with hepatic impairment has not been established, therefore amlodipine should be administered with caution (see section 4.4 “Special warnings and precautions for use”).

The tablets should be taken with a glass of water independently from meals.

Amlodipine is contra-indicated in patients with:

• hypersensitivity to amlodipine, dihydropyridine derivatives or to any of the excipients

• severe hypotension

• shock, including cardiogenic shock

• heart failure after acute myocardial infarction (during the first 28 days)

• obstruction of the outflow tract of the left ventricle (e.g. high grade aortic stenosis)

•unstable angina pectoris

Amlodipine should be administered with caution to patients with low cardiac reserve.

Patients with heart failure

Patients with cardiac failure should be treated with caution. In a long-term study including patients suffering from severe heart failure (NYHA grade III and IV) the reported incidence of pulmonary oedema was higher in the amlodipine treated group than in the placebo group, but this was not indicating an aggravation of the heart failure (see Section 5.1 „Pharmacodynamic properties“).

Use in patients with impaired hepatic function

The half-life of amlodipine is prolonged in patients with impaired liver function; dosage recommendations have not been established. Amlodipine should therefore be administered with caution in these patients.

Use in elderly patients

In the elderly, increase of the dosage should take place with care (see Section 5.2 “Pharmacokinetic properties”).

Use in children

Amlodipine should not be given to children due to insufficient clinical experience.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Effects of other medicinal products on amlodipine

CYP3A4 inhibitors: A study of elderly patients has shown that diltiazem inhibits metabolism of amlodipine, probably via CYP3A4, since plasma concentration increases by approx. 50% and the effect of amlodipine is increased. It cannot be excluded that stronger inhibitors of CYP3A4 (i.e. ketoconazole, itraconazole, ritonavir) increase the plasma concentration of amlodipine to a greater extent than diltiazem. Caution should be exercised in combination of amlodipine and CYP3A4 inhibitors.

CYP3A4 inducers: There is no information available on the effect of CYP3A4 inducers (i.e. rifampicin, St. John's wort) on amlodipine. Co-administration may lead to reduced plasma concentration of amlodipine. Caution should be exercised in combination of amlodipine and CYP3A4 inducers.

In clinical interaction studies grapefruit juice, cimetidine, aluminium/magnesium (antacid) and sildenafil did not affect the pharmacokinetics of amlodipine.

Effects of amlodipine on other medicinal products

Amlodipine may potentiate the effect of other antihypertensives as beta-adrenoceptor blocking agents, ACE-inhibitors, alpha-1-blockers and diuretics. In patients with an increased risk (for example after myocardial infarction) the combination of a calcium channel blocker with a beta-adrenoceptor blocking agent may lead to heart failure, to hypotension and to a (new) myocardial infarction.

In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or ciclosporin.

There is no effect of amlodipine on laboratory testing.

There are no adequate data from the use of amlodipine in pregnant women.

In animal studies effects on reproduction were found at high dosages (see section 5.3 “Preclinical safety data”). The potential risk for humans is unknown. Accordingly amlodipine should not be used during pregnancy unless clearly needed.

It is not known whether amlodipine is excreted in breast milk. It is advised to stop breastfeeding during treatment with amlodipine.

In patients suffering from dizziness, headache, fatigue or nausea the ability to react may be impaired.

Blood and lymphatic system disorders:

Endocrine disorders:

Metabolism and nutrition disorders:

Nervous system disorders:

Eye disorders:

Psychiatric disorders:

Ear and labyrinth disorders:

Cardiac disorders:

Vascular disorders:

Respiratory, thoracic and mediastinal disorders:

Gastrointestinal disorders:

Hepato-biliary disorders:

Skin and subcutaneous tissue disorders:

Musculoskeletal, connective tissue and bone disorders:

Renal and urinary disorders:

Reproductive system and breast disorders:

General disorders and administration site conditions:

In humans, experience with intentional overdose is limited. Available data suggest that overdose (>100 mg) could result in excessive peripheral vasodilatation with subsequent marked and probably prolonged systemic hypotension.

Clinically significant hypotension due to amlodipine overdose calls for active cardiovascular support including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output.

A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade. Gastric lavage may be worthwhile in some cases. In healthy volunteers the use of charcoal up to 2h after administration of amlodipine 10mg has been shown to reduce the absorption rate of amlodipine.Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit.

Pharmacotherapeutic group: Dihydropyridine derivatives

ATC code: C08C A01

Amlodipine is a calcium antagonist and inhibits the influx of calcium ions into cardiac and smooth muscle cells. The mechanism of the antihypertensive action is due to the direct spasmolytic effect on vascular smooth muscle cells. The precise mechanism by which amlodipine relieves angina pectoris has not been fully determined, but the following two actions play a role:

1. Amlodipine dilates peripheral arterioles and thus reduces the peripheral resistance (afterload) against which the heart pumps. This unloading of the heart reduces myocardial energy consumption and oxygen requirements.

2. Dilatation of the main coronary arteries and the coronary arterioles also probably plays a role in its action. This dilation increases the supply of oxygen to myocardiac muscle in patients with Prinzmetal anginal attack.

In patients with hypertension, once daily dosing provides clinically significant reductions of blood pressure (in both supine and standing positions) that persist for 24 hours.

In patients with angina pectoris, once daily administration of amlodipine increases total exercise time, the delay of occurrence of anginal attack and the delay of the occurrence of a 1-mm ST interval. Amlodipine decreases both attack frequency and glyceryl trinitrate tablet consumption.

In haemodynamic studies in patients with heart failure and in clinical studies based on exercise tests in patients with NYHA class II-IV cardiac decompensation, amlodipine was found not to cause any clinical deterioration, as measured by exercise tolerance, left ventricular ejection fraction and clinical signs and symptoms.

In a placebo-controlled study (PRAISE) designed to evaluate patients with NYHA class III-IV cardiac decompensation treated with digoxin, diuretics and ACE inhibitors, amlodipine was shown not to cause any increase in the risk of death or in the combined risk of mortality and morbidity in patients with cardiac decompensation.

Patients with cardiac failure should be treated with caution. In a long-term study including patients suffering from severe heart failure (NYHA grade III and IV) the reported incidence of pulmonary oedema was higher in the amlodipine treated group than in the placebo group, but this was not indicating an aggravation of the heart failure.

Absorption/Distribution

After oral administration of therapeutic doses amlodipine is slowly absorbed from the gastrointestinal tract. The absorption of amlodipine is unaffected by the concomitant intake of food. The absolute bioavailability of the unchanged compound is estimated as 64-80%. Peak plasma levels are reached 6 to 12 hours post-dose. The volume of distribution is about 20 l/kg. The pKa of amlodipine is 8.6. Plasma protein binding in vitro is approximately 98%.

Metabolism/Elimination

Steady state plasma levels are reached after 7-8 consecutive days.

Amlodipine is predominantly metabolised to inactive metabolites. About 60% of the administered dose is excreted in the urine, about 10% of which is in the form of unchanged amlodipine.

In the elderly

The time to reach peak plasma concentrations is the same in elderly and younger patients. Clearance may be reduced in elderly patients so that the area under the curve (AUC) and the terminal elimination half-life are increased. The recommended dosage regimen for elderly patients is however the same, although caution should be exercised when increasing the dosage.

In patients with impaired renal function

Amlodipine is extensively biotransformed to inactive metabolites. Ten percent of the substance is excreted unchanged in the urine. Changes in amlodipine plasma concentration are not correlated with the degree of renal impairment. In these patients amlodipine may be administered at the normal dosage. Amlodipine is not dialysable.

Patients with hepatic impairment:

The half-life of amlodipine is prolonged in patients with impaired hepatic function.

Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. In animal studies with respect to the reproduction in rats at high doses delayed parturition, difficult labour and impaired foetal and pup survival were seen.

Lactose monohydrate

Povidone K 30

Povidone K 90

Microcrystalline cellulose

Crospovidone

Sodium stearyl fumarate

Not applicable.

36 months.

Do not store above 25°C.

Store in the original pack.

Al/Al blister packs with 10, 20, 28, 30, 50, 98,100 tablets

Not all pack sizes may be marketed.

No special requirements.

Genus Pharmaceuticals Limited

T/A Genus Pharmaceuticals

Park View House

65 London Road

Berkshire RG14 1JN

United Kingdom

PL 06831/0107

19 April 2004

11 June 2008